Ophthotech Corporation, a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, for dry and wet forms of age-related macular degeneration, a disorder of the central portion of the retina known as the macula. Ophthotech Corporation has a research agreement with the University of Massachusetts Medical School to utilize the minigene therapy approach and novel gene delivery technologies to target retinal diseases. The company was founded in 2007 and is based in New York, New York.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OPHT
CUSIPN/A
Phone212-845-8200
Debt
Debt-to-Equity RatioN/A
Current Ratio16.20
Quick Ratio16.20
Price-To-Earnings
Trailing P/E Ratio0.75
Forward P/E Ratio-1.52
P/E GrowthN/A
Sales & Book Value
Annual Sales$209.98 million
Price / Sales0.41
Cash Flow$3.1867 per share
Price / Cash0.75
Book Value$1.06 per share
Price / Book2.25
Profitability
EPS (Most Recent Fiscal Year)$3.17
Net Income$114.20 million
Net MarginsN/A
Return on Equity480.74%
Return on Assets91.25%
Miscellaneous
Employees38
Outstanding Shares36,200,000
Market Cap$88.32 million
Ophthotech (NASDAQ:OPHT) Frequently Asked Questions
What is Ophthotech's stock symbol?
Ophthotech trades on the NASDAQ under the ticker symbol "OPHT."
How were Ophthotech's earnings last quarter?
Ophthotech Corp (NASDAQ:OPHT) released its earnings results on Wednesday, August, 1st. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, beating analysts' consensus estimates of ($0.39) by $0.02. View Ophthotech's Earnings History.
When is Ophthotech's next earnings date?
What price target have analysts set for OPHT?
3 analysts have issued 1-year price objectives for Ophthotech's stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate Ophthotech's stock price to reach $4.00 in the next year. This suggests a possible upside of 67.4% from the stock's current price. View Analyst Price Targets for Ophthotech.
What is the consensus analysts' recommendation for Ophthotech?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ophthotech in the last year. There are currently 1 sell rating and 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ophthotech.
What are Wall Street analysts saying about Ophthotech stock?
Here are some recent quotes from research analysts about Ophthotech stock:
- 1. Chardan Capital analysts commented, "We remain positive on the company’s relatively low-cost entry into gene therapy (GT) but reiterate our Neutral rating until we gain additional visibility on these assets. Recall both the Leber congenital amaurosis 10 (LCA10) gene therapy to deliver miniCEP290″ and ABCA4 GT in Stargardt disease licensed from 2018, as well as the autosomal dominant retinitis pigmentosa (adRP) asset licensed from the 2018, are preclinical. As such, catalysts are limited and, aside from a possible publication in the near term, are likely to generate meaningful catalysts on a 2020 horizon at best." (8/2/2018)
- 2. According to Zacks Investment Research, "Ophthotech is focused on development of Zimura, after the failure of Fovista program. The company has reassessed its wet age-related macular degeneration (AMD) program and is developing Zimura in combination with anti-VEGF therapy. The company also collaborated with other companies to develop Zimura in combination studies. With no approved products, the company’s revenues are dependent on collaborations, which may be affected by pipeline setbacks. In a major setback, Novartis terminated its agreement following the failure of Fovista in three phase III program on Fovista. The company lost a major source of revenues. Shares have underperformed the industry so far this year." (7/10/2018)
Who are some of Ophthotech's key competitors?
Some companies that are related to Ophthotech include Ra Pharmaceuticals (RARX), BioSpecifics Technologies (BSTC), Savara (SVRA), Minerva Neurosciences (NERV), Seres Therapeutics (MCRB), Innate Pharma (IPHYF), Avid Bioservices (CDMO), Kezar Life Sciences (KZR), resTORbio (TORC), Paratek Pharmaceuticals (PRTK), Corium International (CORI), Sienna Biopharmaceuticals (SNNA), Kala Pharmaceuticals (KALA), Selecta Biosciences (SELB) and Catalyst Pharmaceuticals (CPRX).
Who are Ophthotech's key executives?
Ophthotech's management team includes the folowing people:
- Dr. David R. Guyer, Exec. Chairman (Age 58)
- Mr. Glenn P. Sblendorio M.B.A., CEO, Pres & Director (Age 62)
- Dr. Samir C. Patel M.D., Co-Founder and Consultant (Age 57)
- Mr. David F. Carroll, Sr. VP, CFO & Treasurer (Age 52)
- Mr. Keith Westby M.B.A., Sr. VP & COO (Age 43)
Has Ophthotech been receiving favorable news coverage?
News stories about OPHT stock have been trending positive recently, according to Accern. Accern rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Ophthotech earned a coverage optimism score of 0.27 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 48.26 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days. View Recent Headlines for Ophthotech.
Who are Ophthotech's major shareholders?
Ophthotech's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Stonepine Capital Management LLC (5.28%), Acadian Asset Management LLC (3.22%), Renaissance Technologies LLC (2.72%), Dimensional Fund Advisors LP (2.40%), BlackRock Inc. (2.14%) and Connor Clark & Lunn Investment Management Ltd. (2.04%). Company insiders that own Ophthotech stock include A/S Novo, Barbara A Wood, David E Redlick, David Francis Carroll, David R Guyer, Glenn Sblendorio, Henric Bjorn Bjarke, Keith Westby and Samir Chandrakant Patel. View Institutional Ownership Trends for Ophthotech.
Which major investors are selling Ophthotech stock?
OPHT stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, GSA Capital Partners LLP, Russell Investments Group Ltd. and Alambic Investment Management L.P.. Company insiders that have sold Ophthotech company stock in the last year include Barbara A Wood, David Francis Carroll, David R Guyer, Glenn Sblendorio and Keith Westby. View Insider Buying and Selling for Ophthotech.
Which major investors are buying Ophthotech stock?
OPHT stock was bought by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Connor Clark & Lunn Investment Management Ltd., Stonepine Capital Management LLC, Dimensional Fund Advisors LP, BlackRock Inc., Spark Investment Management LLC and Rockefeller Capital Management L.P.. View Insider Buying and Selling for Ophthotech.
How do I buy shares of Ophthotech?
Shares of OPHT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ophthotech's stock price today?
One share of OPHT stock can currently be purchased for approximately $2.39.
How big of a company is Ophthotech?
Ophthotech has a market capitalization of $88.32 million and generates $209.98 million in revenue each year. The biopharmaceutical company earns $114.20 million in net income (profit) each year or $3.17 on an earnings per share basis. Ophthotech employs 38 workers across the globe.
How can I contact Ophthotech?
Ophthotech's mailing address is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. The biopharmaceutical company can be reached via phone at 212-845-8200 or via email at [email protected]
MarketBeat Community Rating for Ophthotech (NASDAQ OPHT)
MarketBeat's community ratings are surveys of what our community members think about Ophthotech and other stocks. Vote "Outperform" if you believe OPHT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPHT will underperform the S&P 500 over the long term. You may vote once every thirty days.
